Adaptimmune Reports P-II (SPEARHEAD-1) Trial Results of Afami-cel for the Treatment of Synovial Sarcoma at CTOS 2022
Shots:
- The P-II (SPEARHEAD-1) trial (cohort 1) evaluating afami-cel for advanced synovial sarcoma or MRCLS
- As data cut off of Aug 2022, the results showed a continued clinical response in heavily pre-treated patients; ORR (39%); m-DoR of 50wks., responses were seen in all subpopulations with higher response rates in female patients while those with higher MAGE-A4 expression also showed lower disease burden at baseline or did not need bridging therapy. The results were consistent with prior results indicating an acceptable safety profile
- Afami-cel promotes tumor infiltration by activating & proliferating cytotoxic T cells and aids in the antitumor response. The company plans to initiate a rolling BLA submission of afami-cel in Q4’22 with expected completion in mid-2023
Ref: Newsfilecrop | Image: Adaptimmune
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
